The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Critical Care Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial
Crit. Care Med. 2022 Aug 31;[EPub Ahead of Print], JG Youssef, P Lavin, DA Schoenfeld, RA Lee, R Lenhardt, DJ Park, JP Fernandez, ML Morganroth, JC Javitt, D JayaweeraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.